Introduction {#S0001}
============

Mild cognitive impairment (MCI) is classified as a transitional state between normal aging and mild dementia.[@CIT0001] Longitudinal studies have found that the annual risk of conversion from MCI to probable Alzheimer's disease (AD) was 10--15%.[@CIT0002],[@CIT0003] Due to the high risk of conversion to AD, MCI has become a major concern for early detection of AD to initiate preventive measures. However, it is difficult to predict progression from MCI to AD, and a significant portion of MCI individuals remain stable or return to a normal cognitive state.[@CIT0004],[@CIT0005]

A number of studies have attempted to identify useful predictors of conversion from MCI to AD, including a number of neuropsychological markers,[@CIT0006]--[@CIT0008] neuroimaging biomarkers,[@CIT0009]--[@CIT0011] genetic markers,[@CIT0012]--[@CIT0014] and biochemical markers[@CIT0015]--[@CIT0018] alone and in various combinations.[@CIT0019],[@CIT0020] Especially, neuroimaging biomarkers, including magnetic resonance imaging (MRI) and positron emission tomography (PET) with fluorodeoxyglucose and beta amyloid tracers, showed high sensitivity and specificity.[@CIT0021] However, they are expensive, are feasible only in specialized medical centers,[@CIT0022] and are not appropriate for use in primary care settings, routine bedside check-ups, preventive health care settings, and large community-based studies.

It is important to identify a relatively simple, time-saving, and cost-effective predictor of AD conversion that can be easily used in a practical clinical setting. Previous studies suggested that the Mini-Mental State Examination (MMSE),[@CIT0023] Clinical Dementia Rating (CDR) Sum of Boxes (CDR-SB),[@CIT0024] and CDR orientation score[@CIT0025] were good candidates for such a simple clinical predictor of AD progression. In this study, we examined the use of specific domains of the MMSE as potential markers of AD conversion. The MMSE has long been widely used as a tool to screen for cognitive impairment.[@CIT0026] The MMSE total score comprises subscores representing each cognitive domain: memory, orientation, attention, language, and construction. Several studies have reported the usefulness of MMSE subscores. More rapid decline in the MMSE language subscore was observed in both language and behavioral variants of frontotemporal degeneration,[@CIT0027] and MMSE subscores were helpful in differentiating between dementia with Lewy bodies and AD.[@CIT0028]

Not all domains of cognitive function deteriorate at the same time during the period of early cognitive changes in AD. In general, the decline of non-memory areas and related functions follow decline of episodic memory.[@CIT0029] Therefore, specific MMSE domains other than memory may be useful for predicting conversion to AD in MCI individuals. However, little is known about this issue. This study was performed to investigate the usefulness of MMSE total and subscale scores for predicting AD dementia progression within a 2-year follow-up period in elderly individuals with MCI.

Materials and Methods {#S0002}
=====================

Study Design and Participants {#S0002-S2001}
-----------------------------

Demographic information and clinical data used in this study were obtained from the Alzheimer's Disease Neuroimaging Initiative 1 (ADNI-1) database ([<http://adni.loni.usc.edu>]{.ul}) on 2 February 2015. The ADNI was launched in 2003 as a public--private partnership led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial MRI, PET, and other biological markers along with clinical and neuropsychological assessments can be combined to measure the progression of MCI and early AD. For up-to-date information, see [<http://www.adni-info.org>]{.ul}. The study protocol was approved by the institutional review board of each participating site, and written informed consent was obtained from all participants. The complete list of ADNI sites' IRBs can be found at:

[<http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf>]{.ul}

From the ADNI-1 cohort, this study included 306 participants who were MCI at baseline evaluation and had at least one 2-year follow-up visit. All individuals with MCI met the current consensus criteria for amnestic MCI:[@CIT0030] a memory complaint by the subject or their representative, objective memory loss measured by education-adjusted scores on the Wechsler Memory Scale Logical Memory II, absence of significant levels of impairment in other cognitive domains, essentially preserved activities of daily living, and an absence of dementia. All of the MCI subjects had total MMSE scores of 24--30 and a CDR of 0.5. Details of inclusion and exclusion criteria for participants can be found at [<http://www.adni-info.org>]{.ul}.

Baseline and Follow-Up Assessments {#S0002-S2002}
----------------------------------

All participants underwent a standardized clinical evaluation based on the study protocol. Neurological assessments included the Alzheimer Disease Assessment Scale--Cognitive (ADAS-Cog),[@CIT0031] MMSE, and CDR-SB. The MMSE scores were divided into subscores for orientation, memory, attention, language, and construction. The data at baseline and 24 months were used to determine AD conversion, and subjects were considered to have progressed to AD if they met the National Institute of Neurological and Communicative Disorders and Stroke--Alzheimer's Disease and Related Disorders (NINCDS-ADRDA) criteria for AD.[@CIT0032]

Statistical Analysis {#S0002-S2003}
--------------------

The subjects were divided into two groups according to the clinical state at the 2-year follow-up evaluation: those who progressed to AD dementia (MCIp group) and those who did not (MCInp group). Between-group comparisons for baseline continuous data, including demographic and clinical data, were performed using two-tailed *t*-tests. Baseline categorical data were analyzed by chi-square test or Fisher's exact test. Logistic regression analysis was performed to examine the ability of MMSE total or subscale scores to predict progression to AD dementia in MCI individuals. For each analysis of the association between MMSE and progression to AD dementia, three models were tested for stepwise control of potential confounders. The first model did not include any covariates; the second model included age, gender, and education as covariates; and the third model included all potential covariates: age, gender, education, and CDR-SR. In all analyses, two-tailed *p*-values \<0.05 were taken to indicate statistical significance.

Results {#S0003}
=======

Presence of AD Progression Within 2-Year Follow-Up Period {#S0003-S2001}
---------------------------------------------------------

All subjects (n = 306) were diagnosed with MCI at baseline assessments. After a 2-year follow-up, 111 (36.3%) had progressed to AD dementia (MCIp group), whereas the remaining 195 (63.7%) had not (MCInp group) ([Table 1](#T0001){ref-type="table"}).Table 1Baseline Characteristics of the Amnestic MCI Group That Did Not Progress to AD Dementia (MCInp Group) and the Group That Did (MCIp Group) at 2-Year Follow-Up (n = 306)MCInp Group (n = 195)MCIp Group (n = 111)p-valueAge (Years)74.75 ± 7.3974.77 ± 7.070.984^†^Sex (Male/ Female)127 (65.13)/ 68 (34.87)69 (62.16)/ 42 (37.84)0.603^‡^Education (Years)15.79 ± 2.9715.72 ± 2.850.831^†^CDR global score0.50.5CDR sum of box1.40 ± 0.701.84 ± 1.00\<0.001^†^MMSE total score27.42 ± 1.7226.62 ± 1.61\<0.001^†^MMSE subscale scoreMMSE memory score4.96 ± 1.024.50 ± 1.10\<0.001^†^ Immediate recall2.96 ± 0.202.98 ± 0.190.323^†^ Delayed recall2.01 ± 1.001.51 ±1.08\<0.001^†^MMSE orientation score9.16 ± 1.008.86 ± 1.030.012^†^Time score4.64 ± 0.664.39 ± 0.750.003^†^ Year 0/15 (2.56)/ 190 (97.44)2 (1.80)/109 (98.20)1.000\* Month 0/13 (1.54)/192 (98.46)4 (3.60)/107 (96.40)0.260\* Week 0/113 (6.67)/182 (93.33)18 (16.22)/93 (83.78)0.008^†^ Day 0/133 (16.92)/162 (83.08)29 (26.13)/82 (73.87)0.054^†^ Season 0/117 (8.72)/178 (91.28)15 (13.51)/96 (86.49)0.187^†^Place score4.52 ± 0.684.47 ± 0.690.503^†^ Hospital 0/120 (10.26)/175 (89.74)10 (9.01)/101 (90.99)0.724^†^ Floor 0/139 (15.38)/165 (84.62)25 (22.52)/86 (77.48)0.118^†^ City 0/115 (7.69)/180 (92.31)3 (2.70)/108 (97.30)0.082\* Area 0/126 (13.33)/169 (86.67)20 (18.02)/91 (81.98)0.270^†^ State 0/12 (1.03)/193 (98.97)1 (0.90)/110 (99.10)1.000\*MMSE attention score4.73 ± 0.794.74 ± 0.720.908^†^MMSE language score8.35 ± 0.578.35 ± 0.570.969^†^ Naming 0/1/20 (0)/0 (0)/195 (100)0 (0)/1 (0.90)/110 (99.10)0.363\* Command 0/1/2/30 (0)/0 (0)/26 (13.33)/169 (86.67)0 (0)/0 (0)/11 (9.91)/100 (90.09)0.467\* Repetition 0/138 (19.45)/157 (80.51)23 (20.72)/88 (72.28)0.882^‡^ Reading 0/10 (0)/195 (100)1 (0.90)/110 (99.10)0.363\* Writing 0/14 (2.05)/191 (97.95)3 (2.70)/108 (97.30)0.707\*MMSE construction score 0/117 (8.72)/178 (91.28)21 (18.92)/90 (81.08)0.012^‡^[^1][^2]

Baseline Characteristics of AD Progression and Non-Progression Groups {#S0003-S2002}
---------------------------------------------------------------------

The baseline demographics and clinical characteristics of the MCIp and MCInp groups are shown in [Table 1](#T0001){ref-type="table"}. There were no significant differences between the two groups with regard to age, sex, education, and CDR global score. The MCIp group had significantly higher CDR-SB scores and lower MMSE total and some MMSE subscores (memory, orientation, and construction) than the MCInp group. In terms of the MMSE memory subscore, the MCIp group showed significantly lower MMSE delayed recall scores than the MCInp group, but there was no significant difference in the MMSE immediate recall score between the two groups. With regard to the MMSE orientation subscore, there was a significant difference between the two groups in time subscore, but not in the place subscore. Among the MMSE time subscores, the week score of the MCIp group was significantly lower (p = 0.008) compared to those of the MCInp group, and the time score was almost significantly lower (p = 0.054). However, there were no significant differences in other orientation subscale scores between the two groups.

Association of MMSE Total and Orientation Score with AD Progression {#S0003-S2003}
-------------------------------------------------------------------

As shown in [Table 2](#T0002){ref-type="table"}, MMSE total score and memory, orientation, and construction subscale scores showed significant negative associations with AD progression after controlling for potential confounding variables, whereas attention and language score showed no such relations. [Table 3](#T0003){ref-type="table"} shows that the delayed recall score in the memory subscale scores and the time score in the orientation subscale scores were negatively associated with AD progression, whereas the immediate recall and place scores showed no such relations.Table 2Results of Multiple Logistic Regression Analysis to Assess the Relationships of MMSE Total and Subscale Scores with AD Progression at 2-Year Follow-Up in Individuals with MCIAD Progression at Two-Year Follow-UpOR (95% CI)P valueMMSE total scoreModel 10.758 (0.657 to 0.874)\<0.001Model 20.754 (0.652 to 0.872)\<0.001Model 30.787 (0.677 to 0.914)0.002MMSE subscale scoreMemory scoreModel 10.663 (0.531 to 0.829)\<0.001Model 20.662 (0.530 to 0.828)\<0.001Model 30.673 (0.534 to 0.847)0.001Orientation scoreModel 10.750 (0.597 to 0.943)0.014Model 20.751 (0.595 to 0.948)0.016Model 30.827 (0.649 to 1.055)0.127Attention scoreModel 11.018 (0.75- to 1.382)0.908Model 21.017 (0.745 to 1.388)0.917Model 31.037 (0.750 to 1.434)0.826Language scoreModel 11.008 (0.668 to 1.523)0.969Model 21.014 (0.670 to 1.534)0.948Model 30.972 (0.633 to 1.493)0.898Construction scoreModel 10.409 (0.206 to 0.814)0.011Model 20.405 (0.203 to 0.811)0.011Model 30.382 (0.186 to 0.783)0.009[^3][^4] Table 3Results of Multiple Logistic Regression Analysis to Assess the Relationships of MMSE Memory and Orientation Subscale Scores with AD Progression at 2-Year Follow-Up in Individuals with MCIAD Progression at Two-Year Follow-UpOR (95% CI)P valueMMSE memory-immediate recall scoreModel 12.060 (0.470 to 9.026)0.338Model 22.082 (0.467 to 9.289)0.337Model 32.090 (0.485 to 8.998)0.322MMSE memory-delayed recall scoreModel 10.639 (0.509 to 0.803)\<0.001Model 20.639 (0.509 to 0.803)\<0.001Model 30.648 (0.512 to 0.820)\<0.001MMSE orientation-time scoreModel 10.612 (0.439 to 0.855)0.004Model 20.615 (0.439 to 0.860)0.004Model 30.689 (0.485 to 0.980)0.038MMSE orientation-place scoreModel 10.890 (0.635 to 1.249)0.501Model 20.900 (0.639 to 1.268)0.548Model 30.983 (0.689 to 1.403)0.926[^5][^6]

To assess the relationships of time subscale scores with AD progression, a series of logistic regression analyses were conducted in four steps ([Table 4](#T0004){ref-type="table"}). In the first step, we tested one-item models: among the five models, the MMSE time--week (MMSE-W) model was statistically significant. In the second step, we tested two-item models, which included the MMSE-W model, and found that only the MMSE time--week and day (MMSE-WD) model was significant. In the third step, MMSE time--season, week, and day (MMSE-SWD) and MMSE time--month, week, and day (MMSE-MWD) were significant among the three-item models that included MMSE-WD. In the fourth step, all four-item models that included MMSE time-SWD or -MWD were significant.Table 4Results of Multiple Logistic Regression Analysis to Assess the Relationship of MMSE Time Subscale Scores with AD Progression at 2-Year Follow-Up in Individuals with MCIAD Progression at Two-Year Follow-UpOR (95% CI)P valueOne item modelMMSE time-season (S)Model 10.611 (0.292 to 1.278)0.191Model 20.610 (0.292 to 1.276)0.189Model 30.710 (0.329 to 1.534)0.384MMSE time-year (Y)Model 11.434 (0.274 to 7.518)0.670Model 21.451 (0.276 to 7.621)0.660Model 31.708 (0.310 to 9.394)0.538MMSE time-month (M)Model 10.418 (0.092 to 1.902)0.259Model 20.423 (0.093 to 1.936)0.268Model 30.504 (0.101 to 2.512)0.403MMSE time-week (W)Model 10.369 (0.173 to 0.786)0.010Model 20.369 (0.172 to 0.793)0.011Model 30.498 (0.226 to 1.098)0.084MMSE time-day (D)Model 10.576 (0.327 to 1.014)0.056Model 20.582 (0.329 to 1.029)0.063Model 30.626 (0.347 to 1.129)0.120Two items model with WMMSE time-SWModel 10.506 (0.303 to 0.843)0.009Model 20.508 (0.304 to 0.848)0.010Model 30.618 (0.362 to 1.056)0.078MMSE time-YWModel 10.463 (0.233 to 0.918)0.027Model 20.465 (0.232 to 0.929)0.030Model 30.618 (0.301 to 1.268)0.189MMSE time-MWModel 10.400 (0.205 to 0.779)0.007Model 20.402 (0.205 to 0.787)0.008Model 30.514 (0.255 to 1.037)0.063MMSE time-WDModel 10.526 (0.341 to 0.812)0.004Model 20.527 (0.339 to 0.818)0.004Model 30.603 (0.382 to 0.953)0.030Three items model with WDMMSE time-SWDModel 10.572 (0.398 to 0.822)0.003Model 20.574 (0.398 to 0.827)0.003Model 30.649 (0.443 to 0.951)0.026MMSE time-YWDModel 10.564 (0.372 to 0.856)0.007Model 20.565 (0.371 to 0.863)0.008Model 30.650 (0.419 to 1.009)0.055MMSE time-MWDModel 10.536 (0.356 to 0.806)0.003Model 20.536 (0.354 to 0.812)0.003Model 30.608 (0.394 to 0.938)0.024Four items model with S(or M)WDMMSE time-SYWDModel 10.600 (0.422 to 0.853)0.004Model 20.602 (0.422 to 0.858)0.005Model 30.682 (0.470 to 0.989)0.043MMSE time-SMWDModel 10.589 (0.418 to 0.829)0.002Model 20.591 (0.418 to 0.834)0.003Model 30.661 (0.461 to 0.947)0.024MMSE time-YMWDModel 10.568 (0.383 to 0.843)0.005Model 20.570 (0.382 to 0.849)0.006Model 30.649 (0.427 to 0.986)0.043[^7][^8]

Discussion {#S0004}
==========

This study was performed to investigate whether specific MMSE domains are useful predictors of AD conversion in MCI individuals through a 2-year follow-up. This is the first longitudinal study using MMSE subscores to determine AD conversion among individuals with MCI. Our results showed that MMSE subscores for orientation and construction, as well as for memory, are useful predictors of conversion from MCI to AD.

As AD is characterized by a long preclinical period in which defects in episodic memory can be detected,[@CIT0033] episodic memory decline is a well-known predictor of AD progression.[@CIT0034] In accordance with these results, we showed that the MMSE delayed recall subscore predicted conversion to AD. Furthermore, our results showed that the MMSE time orientation subscore could be useful for predicting AD conversion in MCI. These results were consistent with a previous study showing that memory and temporal orientation were initial MMSE items that were lost during the course of AD.[@CIT0035] Another study also demonstrated that the MMSE orientation for time predicted cognitive decline in elderly people.[@CIT0036]

In terms of the usefulness of the MMSE orientation score, one possible interpretation is that orientation consists of multiple cognitive domains, including attention and visuospatial perception as well as memory.[@CIT0025] Episodic memory impairment is the earliest symptom of AD, followed by attention and visuospatial dysfunction.[@CIT0037] Individuals with MCI already have reduced memory performance,[@CIT0038] so examination of orientation, which contains more information in addition to memory, may be more effective compared to examination of memory alone. In terms of orientation-related neural substrates, a clinicopathological study reported that both temporal and spatial disorientation in AD were related to neurofibrillary tangle densities in the hippocampus, superior parietal, and posterior cingulate cortex.[@CIT0039] In contrast to this result, we found that place orientation could not predict AD conversion, whereas time orientation showed predictive capability. A previous PET study showed differences in the biological underpinnings of time and place orientation: time orientation was associated with the rate of glucose metabolism in the posterior cingulate gyri and right middle temporal gyrus, whereas place orientation was correlated with glucose metabolism in the right posterior cingulate gyrus.[@CIT0040] Our results also suggested that time orientation may have specific neural substrates that are distinct from those for place orientation.

We found that the MMSE construction score was a valid predictor of AD conversion. The construction subscore was obtained using an interlocking pentagon copying item, which is given a maximum score of 1 point. The pentagon copying test is known to be an effective method for distinguishing between patients with dementia with Lewy bodies from those with AD.[@CIT0041] Our results demonstrated the possibility of using the pentagon copying test as a screening tool for AD conversion. To complement the crude scoring method (0/1 score) and increase the ability to identify subtle differences, further studies using a wider range of scoring methods, eg, Bender--Gestalt test (0--4-point scores) or the Qualitative Scoring MMSE Pentagon Test (0--13-point scores),[@CIT0042] should be performed in the future.

The use of the MMSE subscores has a number of merits, including simplicity of administration and ease of use and interpretation of the results. In addition, it is possible to obtain information about AD conversion through existing routine tests without additional tests. However, this study also has several limitations. The MMSE score is known to be highly affected by age, sex, and education.[@CIT0043],[@CIT0044] In general assessments, the normality of the MMSE total score was determined by using age-, sex-, and education-adjusted normative data; unfortunately, no such norms are available for the subscores of MMSE. However, these factors are unlikely to have affected the results of this study because we found no significant differences in age, sex, or education level between the MCIp and MCInp groups, and the results remained significant after controlling for age, sex, and education. Another issue was that the NINCDS-ADRDA criteria were used to determine AD conversion, instead of using biomarkers of AD. The objective of the present study was to investigate predictors of AD conversion in a practical clinical setting, so we excluded these biomarkers. The importance of biomarkers in AD research is growing, and the ADNI study included comprehensive measures of biomarkers, such as MRI, FDG, and amyloid PET. Outside the practical clinical setting, further research using biomarker changes as outcome variables in addition to clinical AD conversion is required. Finally, we used only 2-year follow-up data to investigate the earliest predictors of AD conversion within a short period. However, further studies with a longer follow-up period are required.

Conclusion {#S0005}
==========

Our findings emphasize the importance of assessing orientation and construction domains to identify subjects at high risk of AD conversion among elderly people whose memory function is already impaired. In terms of simplicity, rapid administration, and ease of interpretation, MMSE subscales of memory, orientation, and construction could be useful screening tools for predicting conversion to AD from MCI in practical clinical settings.
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[^1]: **Notes:** Data are presented as mean ± SD or number (%). ^†^ Student's *t*-test; ^‡^ chi-square test; \*Fisher's exact test.

[^2]: **Abbreviations:** MCI, mild cognitive impairment; AD, Alzheimer's disease; CDR, Clinical Dementia Rating; MMSE, Mini-Mental State Examination.

[^3]: **Notes:** Model 1 did not include any covariates. Model 2 included age, sex, and education as covariates. Model 3 included age, sex, education, and CDR-SB score as covariates.

[^4]: **Abbreviations:** OR, odds ratio; CI, confidence interval.
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